Prestige BioPharma Limited (KRX:950210)
South Korea flag South Korea · Delayed Price · Currency is KRW
14,460
+80 (0.56%)
At close: Apr 16, 2025, 3:30 PM KST

Prestige BioPharma Income Statement

Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 2019
Revenue
5,869689.08161.84---
Upgrade
Revenue Growth (YoY)
1582.73%325.77%----
Upgrade
Cost of Revenue
1,2181,21833.94228.95284.85123.87
Upgrade
Gross Profit
4,651-528.79127.9-228.95-284.85-123.87
Upgrade
Selling, General & Admin
51,52645,47658,23154,42216,4329,564
Upgrade
Operating Expenses
67,76061,709-906.28122,46018,09912,769
Upgrade
Operating Income
-63,109-62,2381,034-122,689-18,384-12,893
Upgrade
Interest Expense
-7,404-7,404-950.8-18.85-6.2-
Upgrade
Interest & Investment Income
12,40212,40210,4642,729158.22523.21
Upgrade
Earnings From Equity Investments
---16.96---
Upgrade
Currency Exchange Gain (Loss)
-4,232-4,232-924.24-1,592-4,62057.88
Upgrade
Other Non Operating Income (Expenses)
3,7226,6934,0342,282414.8-1,986
Upgrade
EBT Excluding Unusual Items
-58,620-54,77913,639-119,288-22,437-14,299
Upgrade
Gain (Loss) on Sale of Investments
----15,081-
Upgrade
Gain (Loss) on Sale of Assets
89.489.472.12211.59-0.36-
Upgrade
Asset Writedown
---15,807-91,573--599.83
Upgrade
Pretax Income
-58,531-54,689-2,095-210,649-7,357-14,898
Upgrade
Income Tax Expense
284.99408.68763.28800.6634.0898.47
Upgrade
Earnings From Continuing Operations
-58,816-55,098-2,859-211,450-7,391-14,997
Upgrade
Minority Interest in Earnings
28,96222,17720,428---
Upgrade
Net Income
-29,854-32,92117,569-211,450-7,391-14,997
Upgrade
Net Income to Common
-29,854-32,92117,569-211,450-7,391-14,997
Upgrade
Shares Outstanding (Basic)
606060605243
Upgrade
Shares Outstanding (Diluted)
606060605243
Upgrade
Shares Change (YoY)
-0.07%--16.46%20.98%7.27%
Upgrade
EPS (Basic)
-496.51-547.81292.35-3518.53-143.23-351.60
Upgrade
EPS (Diluted)
-496.51-547.81292.35-3796.17-143.23-351.60
Upgrade
Free Cash Flow
-91,000-68,091-108,636-102,336-16,396-13,761
Upgrade
Free Cash Flow Per Share
-1513.45-1133.03-1807.71-1702.88-317.73-322.63
Upgrade
Gross Margin
79.25%-76.74%79.03%---
Upgrade
Operating Margin
-1075.25%-9032.13%639.01%---
Upgrade
Profit Margin
-508.65%-4777.60%10855.90%---
Upgrade
Free Cash Flow Margin
-1550.46%-9881.47%-67125.45%---
Upgrade
EBITDA
-44,533-45,97112,684-118,822-16,717-11,708
Upgrade
EBITDA Margin
--7837.31%---
Upgrade
D&A For EBITDA
18,57616,26711,6503,8671,6671,185
Upgrade
EBIT
-63,109-62,2381,034-122,689-18,384-12,893
Upgrade
EBIT Margin
--639.01%---
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.